The latest price target for Lyell Immunopharma (NASDAQ:LYEL) was reported by HC Wainwright & Co. on November 12, 2024. The analyst firm set a price target for $1.00 expecting LYEL to rise to within 12 months (a possible 63.21% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Lyell Immunopharma (NASDAQ:LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma reiterated their neutral rating.

There is no last upgrade for Lyell Immunopharma

The last downgrade for Lyell Immunopharma Inc happened on October 30, 2024 when B of A Securities changed their price target from $6 to $1 for Lyell Immunopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a reiterated with a price target of $1.00 to $1.00. The current price Lyell Immunopharma (LYEL) is trading at is $0.61, which is out of the analyst’s predicted range.